Hua Medicine (Shanghai) Ltd.（02552.HK）股价、图表、新闻与AI分析

Q: Hua Medicine (Shanghai) Ltd. 的 CEO 是谁？

Dr. Li Chen 是 Hua Medicine (Shanghai) Ltd. 的 Chief Executive Officer，自 2010 加入公司。

Q: HUA MEDICINE-B 股票的价格表现如何？

HUA MEDICINE-B 的当前价格为 $3.25，在上个交易日 下降 了 4.69%。

Q: Hua Medicine (Shanghai) Ltd. 的主要业务主题或行业是什么？

Hua Medicine (Shanghai) Ltd. 属于 Pharmaceuticals 行业，该板块是 Health Care

Q: Hua Medicine (Shanghai) Ltd. 的市值是多少？

Hua Medicine (Shanghai) Ltd. 的当前市值是 $3.2B

主页

股票

02552.HK

HUA MEDICINE-B (02552.HK)

Hua Medicine (Shanghai) Ltd.

HK$3.25

-4.69%

$-0.16

休市： Jan 16, 16:00:00 HKT

关键数据

前收盘价

$3.41

开盘价

$3.41

当日区间

$3.2 - $3.41

52周范围

$1.24 - $4.95

交易量

5.3M

平均成交量

3.5M

每股收益（TTM）

1.21

股息收益率

市值

$3.2B

什么是 HUA MEDICINE-B？

Hua Medicine Ltd. provides drug discovery and development services. The company is headquartered in Shanghai, Shanghai and currently employs 285 full-time employees. The company went IPO on 2018-09-14. The firm is also engaged in the commercialization of HuaTangNing products. The Company’s main product pipeline dorzagliatin or HMS5552 is a glucokinase activator or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The firm mainly conducts its business in the domestic market.

功能特性

交易策略